(NASDAQ:DAWN), Commercial execution delivers best quarter launch-to-date with growth across all dimensions of core business Raising OJEMDA full-year 2025 net product revenue guidance to $145 to $150 million Three-year FIREFLY-1 data to be released in oral presentation at Society for Neuro-Oncology on Nov. 23, 2025 Ended the third quarter with $451.6 million in cash, cash […]
(NASDAQ:LSTA), BASKING RIDGE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today highlighted positive preclinical data as announced by Lisata's licensing partner, Catalent, Inc. (“Catalent”), at the 16th Annual
(NASDAQ:CYTK), SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the following investor conferences in November: Stifel 2025 Healthcare Conference: Fireside chat on Tuesday, November 11, 2025 at 11:20 AM Eastern Time in New York, NY. Jefferies Global
(NASDAQ:JFB), Total contract valued at $100 million Lantana, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) — JFB Construction Holdings (Nasdaq: JFB), a real estate development and construction company focused on hospitality, commercial, industrial, and residential property development, today announced that it has been approved for the issuance of an $18.9 million bond to act as general
(CNSX:JUSH),(CNSX:JUSH.CN),(OTC US:JUSHF),(Other OTC:JUSHF), Continued Topline Momentum with Revenue of $65.7 million, Up Sequentially and Year-over-Year Gross Profit of $30.7 million, with Margin Expanding by 220 bps Sequentially and 125 bps Year-over-Year to 46.7% Ongoing Enhancements Across Grower-Processor Footprint Driving Stronger Sales, Profitability, and Margin Performance BOCA RATON, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) — Jushi
(NASDAQ:ABOS), NEWTON, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) — Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the Stifel Healthcare Conference on Tuesday, Nov. 11, 2025, at
Kratos Reports Third Quarter 2025 Financial Results GlobeNewswire November 04, 2025 Third Quarter 2025 Revenues of $347.6 Million Reflect 26.0 Percent Growth and 23.7 Percent Organic Growth Over Third Quarter 2024 Revenues of $275.9 Million Unmanned Systems Third Quarter 2025 Revenues of $87.2 Million Reflect 35.8 Percent Organic Growth Over Third Quarter 2024 Revenues of
Day One Reports Third Quarter 2025 Financial Results and Corporate Progress GlobeNewswire November 04, 2025 Commercial execution delivers best quarter launch-to-date with growth across all dimensions of core business Raising OJEMDA full-year 2025 net product revenue guidance to $145 to $150 million Three-year FIREFLY-1 data to be released in oral presentation at Society for Neuro-Oncology
Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent Data from Catalent's preclinical studies evaluating certepetide as a SMARTag(R) ADC payload showed both improved tumor selective penetration and efficacy GlobeNewswire November 04, 2025 BASKING RIDGE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) — Lisata Therapeutics,
Cytokinetics to Participate in November Investor Conferences GlobeNewswire November 04, 2025 SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the following investor conferences in November: Stifel 2025 Healthcare Conference: Fireside chat on Tuesday, November 11, 2025 at